SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff amid weakness in AI-infrastructure stocks has put its heavy debt burden, financing costs and insider selling at the center of the debate; a Goldman Sachs upgrade and reported ARK buying have not eased the concern for many traders. Bears warn of dilution or default, while bulls point to contracted AI-compute demand and see buying opportunities, leaving the stocks support levels in sharp focus.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to upcoming share unlocks, reported insider selling, and a TD Cowen price-target cut as sources of pressure. The debate is whether the decline is temporary supply and AI-sector weakness or reflects deeper concerns about customer concentration, growth, and valuation; some traders see an oversold opportunity while others expect further downside.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff is dominated by concerns that its convertible-note financing and added shares will dilute investors, alongside weakness across AI and data-center infrastructure stocks. Bears question management, debt and execution, while some holders see the decline as an oversold pullback and remain bullish on the companys longer-term AI hosting opportunity.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending, with CEO Hock Tans warning that some AI investing resembles gambling adding to concerns. Bears see his comments and AI-credit risks as reasons for continued weakness, while bulls argue demand and Broadcoms fundamentals remain intact and view the decline as a buying opportunity.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the results as evidence of a turnaround and welcome the rebound, while skeptics question whether the improvement will last and point to the stocks volatile reaction despite the strong report.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb toward a 52-week high and a key round-number resistance level is driving discussion, with traders highlighting bullish chart momentum and a defensive rotation into pharma. Others question whether the move can hold, pointing to resistance and the absence of a single clear near-term catalyst.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Concerns about Oracles debt-heavy AI data-center buildout, rising credit risk and weak free cash flow dominate discussion, alongside pressure on AI infrastructure stocks. Traders are split between seeing the spending and backlog as a path to future cloud growth and fearing that borrowing costs and execution risks could overwhelm demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI-infrastructure stocks, fueled by concerns about neocloud financing, debt and whether heavy AI spending will generate sufficient returns. Traders are split on whether the rebound from oversold levels signals a recovery or a temporary bounce, with some arguing Nebius is better positioned than more debt-heavy peers.

Aventus Network

Aventuss disclosure that an attacker exploited a code vulnerability to mint and sell AVT has fueled attention to the tokens sharp swings in thin markets; the team says the exploit is patched and the attacker has exited. Traders are split between hoping for a low-float rebound and worrying about concentrated holdings, supply changes, and persistent selling pressure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a broad AI and semiconductor selloff, as traders debate whether heavy AI infrastructure spending and debt financing can generate adequate returns. Bulls point to continued chip demand and company announcements, while skeptics warn of an AI spending bubble and further sector weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GMED or AXGN: Which Is the Better Value Stock Right Now?

GMED vs. AXGN: Which Stock Is the Better Value Option?

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week

Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the WeekPR NewswireVANCOUVER, BC, Oct. 3, 2026VANCOUVER, BC, Oct. 3, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big...

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen is acquiring BioCircuit Technologies for $200 million to add sutureless NerveTape to its portfolio, funded by a public stock offering.read more...

Axogen To Acquire BioCircuit Technologies

(RTTNews) - Axogen (AXGN) has entered into a definitive agreement to acquire BioCircuit Technologies, a privately held medical device company and developer of NerveTape, the first FDA-approved device for sutureless nerve repair. Axogen will acquire BioCircuit for total considerat...

Axogen (AXGN) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology

Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology PR...

NZS Capital Added Axogen (AXGN) as an Optionality Position

NZS Capital Added Axogen (AXGN) as an Optionality Position...

Axogen, Inc. engages in the development and marketing of surgical solutions for peripheral nerve regeneration and repair. It provides products and educational resources to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Avive Soft Tissue Membrane, AcroVal Neurosensory and Motor Testing System, and AxoTouch Two-Point Discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Axogen Inc.

AXGN Stock Rises After FDA Approves Nerve Repair Graft

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves.</li><li>It eliminates the need for a secondary nerve-harvest surgery, helping lower the risk of complications and aiding faster recovery.</li><li>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026.</li></ul><p>Shares of Axogen Inc. (AXGN) were up nearly 12% in Thursday’s opening trade after the company announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its nerve repair graft.</p><p>Axogen announced on late Wednesday that the FDA had approved its Biologics License Application for Avance, which is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.</p><p>Retail sentiment on Stocktwits around the&nbsp;<a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> soared, entering the ‘extremely bullish’ territory from ‘bullish’ a day ago, while message volumes increased to hover at ‘extremely high’ levels from ‘normal’ a day ago.</p><h2 class="st-heading-2">Why Is This Important?</h2><p>Axogen’s Avance nerve graft is a human-tissue-based solution for repairing damaged peripheral nerves. It eliminates the need for a secondary nerve-harvesting surgery, helping reduce the risk of complications and enabling faster recovery.</p><p>“This milestone clarifies and strengthens our regulatory footing and confirms approval for use of Avance as an acceptable therapeutic option for treating peripheral nerve discontinuities in all of Axogen’s present nerve repair use cases,” said Michael Dale, CEO, Axogen.</p><h2 class="st-heading-2">When Will It Be Available?</h2><p>The company expects the commercial availability of the licensed Avance nerve graft product in the second quarter of 2026. Until then, the company will continue to offer Avance under the current tissue framework.</p><p>Axogen cautioned that since Avance is made from human donor tissue, there is a risk of transmitting infectious agents such as viruses.</p><h2 class="st-heading-2">Who Is Avance Aimed At?</h2><p>According to the company, Avance is intended for patients older than one month. These patients may have sensory nerve discontinuity of less than or equal to 25 millimeters.</p><p>For patients with sensory nerve continuity of more than 25 mm or those with mixed and motor nerve discontinuity, Avance has received accelerated approval, according to the company. It noted that continued approval is contingent upon confirmatory clinical trial results.</p><p><a href="https://stocktwits.com/symbol/AXGN">AXGN stock</a> is up 89% year-to-date and 110% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/robotics-stocks-surge-trump-executive-order-reports/cLIXDUjRE1r"><strong>iRobot, Richtech Robotics Stocks Surge As Trump Administration Reportedly Considers Executive Order To Accelerate Development</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities.

Why Is AXGN Stock Rising Today?

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$AXGN Aetna was the last major insurer not covering Avance. 
Their update now classifies Avance as medically necessary for short‑to‑medium sensory nerve gaps ≤30 mm in the upper extremity. 
Coverage jumps from 86% → mid‑90% of commercial lives. This materially expands AxoGen’s market.  Analysts responded immediately: 
Truist: reiterated Buy, PT $60 
Raymond James: PT $53 
H.C. Wainwright: PT $53 
Citizens: PT $55

Mark Drelich

$AXGN Nice. Pretty clear rejection off the lows on good volume, especially in the last hour.

Dustin

$AXGN IMO when we see the 10yr start to trend down a bit we'll see a reversal here. Stuck in a pretty nasty downward channel. Fundamentals haven't changed. Quality bio is going to be a great hedge against the AI/tech giants and $$ should keep rotating. Being patient here and adding bits as we go. GL!

$AXGN Aetna just updated their nerve graft policy. Based on the 18K bid in the green I’m guessing AVANCE is now included! Super

$AXGN 
 
AxoGen closed its BioCircuit acquisition Thursday. NerveTape, which the company calls the first FDA-cleared device for sutureless peripheral nerve repair, is expected to add about 6 million of Q4 revenue and 34 million in 2027. 
 
That 2027 number sits outside AxoGen's guidance. On the at-least-24% growth guide off 225.2 million in 2025 revenue, 34 million is roughly 12% of the guided 2026 base. One tuck-in, a double-digit share of next year's sales. 
 
The Street is split around the close. Truist cut its target to $53 from $60 on Thursday but kept a Buy. Morgan Stanley downgraded to Hold two days earlier. Raymond James raised its target to $53 six days before that. 
 
The tape has fallen five straight days, down 13.8%, closing Friday at 37.39. And Friday saw 9,058 call options trade versus a 322 average.

Krypton Research

$AXGN The market is a discounting mechanism. Perhaps the results for their prostatectomy nerve repair trial are not going to be positive. Hope that’s not the case.

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXGN Axogen Inc.

Fundamentals

Latest AXGN News